Although methylated SEPT9 is the only FDA-approved blood-based biomarker for CRC screening, its clinical utility is hampered by limited sensitivity, detecting only 44.7% of early-stage CRC and 11.2% of advanced adenomas [9]. Here, SEPTIN9 is linked to colorectal carcinoma.